Search

Your search keyword '"Mancinelli, Chiara Rosa"' showing total 26 results
Start Over Author "Mancinelli, Chiara Rosa"
26 results on '"Mancinelli, Chiara Rosa"'

1. Disease‐Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis

Author

Sormani, Maria P, De Rossi, Nicola, Schiavetti, Irene, Carmisciano, Luca, Cordioli, Cinzia, Moiola, Lucia, Radaelli, Marta, Immovilli, Paolo, Capobianco, Marco, Trojano, Maria, Zaratin, Paola, Tedeschi, Gioacchino, Comi, Giancarlo, Battaglia, Mario A, Patti, Francesco, Salvetti, Marco, Nozzolillo, Agostino, Bellacosa, Alessandra, Protti, Alessandra, Di Sapio, Alessia, Signori, Alessio, Petrone, Alfredo, Bisecco, Alvino, Iovino, Aniello, Dutto, Anna, Repice, Anna Maria, Conte, Antonella, Bertolotto, Antonio, Bosco, Antonio, Gallo, Antonio, Zito, Antonio, Sartori, Arianna, Giometto, Bruno, Tortorella, Carla, Antozzi, Carlo, Pozzilli, Carlo, Mancinelli, Chiara Rosa, Zanetta, Chiara, Cordano, Christian, Scandellari, Cinzia, Guaschino, Clara, Gasperini, Claudio, Solaro, Claudio, Fioretti, Cristina, Bezzini, Daiana, Marastoni, Damiano, Paolicelli, Damiano, Vecchio, Domizia, Landi, Doriana, Bucciantini, Elisabetta, Pedrazzoli, Elisabetta, Signoriello, Elisabetta, Sbragia, Elvira, Susani, Emanuela Laura, Curti, Erica, Milano, Eva, Marinelli, Fabiana, Camilli, Federico, Boneschi, Filippo Martinelli, Govone, Flora, Bovis, Francesca, Calabria, Francesca, Caleri, Francesca, Rinaldi, Francesca, Vitetta, Francesca, Corea, Francesco, Crescenzo, Francesco, Teatini, Francesco, Tabiadon, Giulietta, Granella, Franco, Boffa, Giacomo, Lus, Giacomo, Brichetto, Giampaolo, Maniscalco, Giorgia Teresa, Borriello, Giovanna, De Luca, Giovanna, Konrad, Giovanna, Vaula, Giovanna, Marfia, Girolama Alessandra, Mallucci, Giulia, Liberatore, Giuseppe, Salemi, Giuseppe, Miele, Giuseppina, Sibilia, Grazia, Pesci, Ilaria, Brambilla, Laura, Lopiano, Leonardo, Sinisi, Leonardo, Pasquali, Livia, Saraceno, Lorenzo, Chiveri, Luca, Mancinelli, Luca, and Grimaldi, Luigi ME

Subjects
Pneumonia & Influenza, Neurodegenerative, Clinical Research, Autoimmune Disease, Brain Disorders, Lung, Multiple Sclerosis, Pneumonia, Neurosciences, Neurological, Good Health and Well Being, Adolescent, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Humanized, COVID-19, Dimethyl Fumarate, Female, Fingolimod Hydrochloride, Hospitalization, Humans, Immunologic Factors, Immunosuppressive Agents, Intensive Care Units, Interferons, Male, Middle Aged, Mortality, Natalizumab, SARS-CoV-2, Severity of Illness Index, Young Adult, Musc-19 Study Group, Clinical Sciences, Neurology & Neurosurgery
Abstract

ObjectiveThis study was undertaken to assess the impact of immunosuppressive and immunomodulatory therapies on the severity of coronavirus disease 2019 (COVID-19) in people with multiple sclerosis (PwMS).MethodsWe retrospectively collected data of PwMS with suspected or confirmed COVID-19. All the patients had complete follow-up to death or recovery. Severe COVID-19 was defined by a 3-level variable: mild disease not requiring hospitalization versus pneumonia or hospitalization versus intensive care unit (ICU) admission or death. We evaluated baseline characteristics and MS therapies associated with severe COVID-19 by multivariate and propensity score (PS)-weighted ordinal logistic models. Sensitivity analyses were run to confirm the results.ResultsOf 844 PwMS with suspected (n = 565) or confirmed (n = 279) COVID-19, 13 (1.54%) died; 11 of them were in a progressive MS phase, and 8 were without any therapy. Thirty-eight (4.5%) were admitted to an ICU; 99 (11.7%) had radiologically documented pneumonia; 96 (11.4%) were hospitalized. After adjusting for region, age, sex, progressive MS course, Expanded Disability Status Scale, disease duration, body mass index, comorbidities, and recent methylprednisolone use, therapy with an anti-CD20 agent (ocrelizumab or rituximab) was significantly associated (odds ratio [OR] = 2.37, 95% confidence interval [CI] = 1.18-4.74, p = 0.015) with increased risk of severe COVID-19. Recent use (

Published
2021

2. Breakthrough SARS-CoV-2 infections after COVID-19 mRNA vaccination in MS patients on disease modifying therapies during the Delta and the Omicron waves in Italy

Author

Maglione, Alessandro, Sapio, Alessia Di, Signori, Alessio, Laroni, Alice, Iovino, Aniello, Maria Repice, Anna, Mannironi, Antonio, Uccelli, Antonio, Serrati, Carlo, Gabri Nicoletti, Carolina, Lapucci, Caterina, Mancinelli, Chiara Rosa, Cordioli, Cinzia, Bezzini, Daiana, Carmagnini, Daniele, Brogi, Davide, Franciotta, Diego, Landi, Doriana, Nobile Orazio, Eduardo, Cocco, Eleonora, Signoriello, Elisabetta, Nako, Enri, Assandrir, Ester, Marinelli, Fabiana, Baldi, Federica, Ansaldi, Filippo, Bovis, Francesca, Caleri, Francesca, Siciliano, Gabriele, Cola, Gaia, Perego, Germana, Lus, Giacomo, Brichetto, Giampaolo, Icardi, Giancarlo, Bellucci, Gianmarco, Da Rin, Giorgio, Alessandra Marfia, Girolama, Vazzoler, Giulia, Liberatore, Giuseppe, Trivelli, Giuseppe, Callari, Graziella, Gandoglia, Ilaria, Maietta, Ilaria, Schiavetti, Irene, Frau, Jessica, Sticchi, Laura, Pasquali, Livia, Lorefice, Lorena, Carmisciano, Luca, Ruggiero, Lucia, Manzino, Marcello, Salvetti, Marco, Monti Bragadin, Margherita, Chiara Buscarinu, Maria, Gagliardi, Maria, Laura Stromillo, Maria, Pia Sormani, Maria, Ferrò, Maria Teresa, Rilla, Maria Teresa, Clerico, Marinella, Alberto Battaglia, Mario, Ponzano, Marta, Fronza, Marzia, Del Sette, Massimo, Inglese, Matilde, Scialabba, Matteo, Bedognetti, Michele, Ulivelli, Monica, De Rossi, Nicola, De Stefano, Nicola, Gazzola, Paola, Bigi, Rachele, Dubbioso, Raffaele, Reniè, Roberta, Iodice, Rosa, Fabbri, Sabrina, Rasia, Sarah, Rolla, Simona, Platzgummer, Stefan, Cordera, Susanna, Tassinari, Tiziana, Carlini, Valentina, Sormani, Maria Pia, Visconti, Valeria, Stromillo, Maria Laura, Di Sapio, Alessia, Pizzorno, Matteo, Repice, Anna Maria, and Battaglia, Mario Alberto

Published
2022
Full Text
View/download PDF

3. Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies

Author

Maglione, Alessandro, Di Sapio, Alessia, Signori, Alessio, Laroni, Alice, Iovino, Aniello, Repice, Anna Maria, Mannironi, Antonio, Uccelli, Antonio, Serrati, Carlo, Nicoletti, Carolina Gabri, Lapucci, Caterina, Mancinelli, Chiara Rosa, Cordioli, Cinzia, Bezzini, Daiana, Carmagnini, Daniele, Brogi, Davide, Franciotta, Diego, Landi, Doriana, Orazio, Eduardo Nobile, Cocco, Eleonora, Signoriello, Elisabetta, Nako, Enri, Assandri, Ester, Marinelli, Fabiana, Baldi, Federica, Ansaldi, Filippo, Bovis, Francesca, Caleri, Francesca, Siciliano, Gabriele, Cola, Gaia, Perego, Germana, Lus, Giacomo, Brichetto, Giampaolo, Icardi, Giancarlo, bellucci, gianmarco, Rin, Giorgio Da, Marfia, Girolama Alessandra, Vazzoler, Giulia, Liberatore, Giuseppe, Trivelli, Giuseppe, Callari, Graziella, Gandoglia, Ilaria, Maietta, Ilaria, Schiavetti, Irene, Frau, Jessica, Sticchi, Laura, Pasquali, Livia, Lorefice, Lorena, Carmisciano, Luca, Ruggiero, Lucia, Manzino, Marcello, Salvetti, Marco, Bragadin, Margherita Monti, Buscarinu, Maria Chiara, Gagliardi, Maria, Stromillo, Maria Laura, Sormani, Maria Pia, Ferrò, Maria Teresa, Rilla, Maria Teresa, Clerico, Marinella, Battaglia, Mario Alberto, Ponzano, Marta, Fronza, Marzia, Sette, Massimo Del, Inglese, Matilde, Scialabba, Matteo, Bedognetti, Michele, Ulivelli, Monica, De Rossi, Nicola, De Stefano, Nicola, Gazzola, Paola, Bigi, Rachele, Dubbioso, Raffaele, Reniè, Roberta, Iodice, Rosa, Fabbri, Sabrina, Rasia, Sarah, Rolla, Simona, Platzgummer, Stefan, Cordera, Susanna, Tassinari, Tiziana, Carlini, Valentina, and Da Rin, Giorgio

Published
2021
Full Text
View/download PDF

4. Early use of low dose tocilizumab in patients with COVID-19: A retrospective cohort study with a complete follow-up

Author

De Rossi, Nicola, Scarpazza, Cristina, Filippini, Chiara, Cordioli, Cinzia, Rasia, Sarah, Mancinelli, Chiara Rosa, Rizzoni, Damiano, Romanelli, Giuseppe, Cossi, Stefania, Vettoretto, Nereo, Bove, Sergio, Manfredini, Silvano, Beindorf, Eva Andrea, Mosca, Carlo, Scipione, Vittorio, Flamminio, Gigliola, Albini, Elena Albini, Giansiracusa, Paola, and Capra, Ruggero

Published
2020
Full Text
View/download PDF

7. COVID-19 Severity in Multiple Sclerosis: Putting Data Into Context

Author

Sormani, Maria Pia, Schiavetti, Irene, Carmisciano, Luca, Cordioli, Cinzia, Filippi, Massimo, Radaelli, Marta, Immovilli, Paolo, Capobianco, Marco, De Rossi, Nicola, Brichetto, Giampaolo, Cocco, Eleonora, Scandellari, Cinzia, Cavalla, Paola, Pesci, Ilaria, Zito, Antonio, Confalonieri, Paolo, Marfia, Girolama Alessandra, Perini, Paola, Inglese, Matilde, Trojano, Maria, Brescia Morra, Vincenzo, Tedeschi, Gioacchino, Comi, Giancarlo, Battaglia, Mario Alberto, Patti, Francesco, Salvetti, Marco, Abbadessa, Gianmarco, Aguglia, Umberto, Allegorico, Lia, Allegri Rossi, Beatrice Maria, Amato, Maria Pia, Annovazzi, Pietro, Antozzi, Carlo, Appendino, Lucia, Arena, Sebastiano, Baione, Viola, Balgera, Roberto, Barcella, Valeria, Baroncini, Damiano, Barrilà, Caterina, Bellacosa, Alessandra, Bellucci, Gianmarco, Bergamaschi, Roberto, Bergamaschi, Valeria, Bezzini, Daiana, Biolzi, Beatrice, Bisecco, Alvino, Bonavita, Simona, Borriello, Giovanna, Bosa, Chiara, Bosco, Antonio, Bovis, Francesca, Bozzali, Marco, Brambilla, Laura, Buccafusca, Maria, Bucciantini, Elisabetta, Bucello, Sebastiano, Buscarinu, Maria Chiara, Cabboi, Maria Paola, Calabrese, Massimiliano, Calabria, Francesca, Caleri, Francesca, Camilli, Federico, Caniatti, Luisa Maria, Cantello, Roberto, Capra, Ruggero, Capuano, Rocco, Carta, Patrizia, Celani, Maria Grazia, Cellerino, Maria, Cerqua, Raffaella, Chisari, Clara, Clerici, Raffaella, Clerico, Marinella, Cola, Gaia, Conte, Antonella, Conti, Marta Zaffira, Cordano, Christian, Cordera, Susanna, Corea, Francesco, Correale, Claudio, Cottone, Salvatore, Crescenzo, Francesco, Curti, Erica, dʼAmbrosio, Alessandro, DʼAmico, Emanuele, Danni, Maura Chiara, dʼArma, Alessia, Dattola, Vincenzo, de Biase, Stefano, Luca, Giovanna De, Mercanti, Stefania Federica De, De Mitri, Paolo, De Stefano, Nicola, Cava, Marco Della, Napoli, Mario di, Sapio, Alessia Di, Docimo, Renato, Dutto, Anna, Evangelista, Luana, Fanara, Salvatore, Diana, Ferraro, Ferrò, Maria Teresa, Fioretti, Cristina, Fratta, Mario, Frau, Jessica, Fronza, Marzia, Furlan, Roberto, Gajofatto, Alberto, Gallo, Antonio, Gallo, Paolo, Gasperini, Claudio, Ghazaryan, Anna, Giometto, Bruno, Gobbin, Francesca, Govone, Flora, Granella, Franco, Grange, Erica, Grasso, Maria Grazia, Guareschi, Angelica, Guaschino, Clara, Guerrieri, Simone, Guidetti, Donata, Iaffaldano, Pietro, Ianniello, Antonio, Iasevoli, Luigi, Imperiale, Daniele, Infante, Maria Teresa, Iodice, Rosa, Iovino, Aniello, Konrad, Giovanna, Landi, Doriana, Lanzillo, Roberta, Lapucci, Caterina, Lavorgna, Luigi, LʼEpiscopo, Maria Rita, Leva, Serena, Liberatore, Giuseppe, Lo Re, Marianna, Longoni, Marco, Lopiano, Leonardo, Lorefice, Lorena, Lucchini, Matteo, Lus, Giacomo, Maimone, Davide, Malentacchi, Maria, Mallucci, Giulia, Malucchi, Simona, Mancinelli, Chiara Rosa, Mancinelli, Luca, Manganotti, Paolo, Maniscalco, Giorgia Teresa, Mantero, Vittorio, Marangoni, Sabrina, Marastoni, Damiano, Marinelli, Fabiana, Marti, Alessandro, Boneschi, Filippo Martinelli, Masserano Zoli, Federco, Matta, Francesca, Mendozzi, Laura, Meucci, Giuseppe, Miante, Silvia, Miele, Giuseppina, Milano, Eva, Mirabella, Massimiliano, Missione, Rosanna, Moccia, Marcello, Moiola, Lucia, Montepietra, Sara, MontiBragadin, Margherita, Montini, Federico, Motta, Roberta, Nardone, Raffaele, Nicoletti, Carolina Gabri, Nobile-Orazio, Eduardo, Nozzolillo, Agostino, Onofrj, Marco, Orlandi, Riccardo, Palmieri, Anna, Paolicelli, Damiano, Pasquali, Livia, Pastò, Luisa, Pedrazzoli, Elisabetta, Petracca, Maria, Petrone, Alfredo, Piantadosi, Carlo, Pietroboni, Anna M, Pinardi, Federica, Ponzano, Marta, Portaccio, Emilio, Pozzato, Mattia, Pozzilli, Carlo, Prosperini, Luca, Protti, Alessandra, Ragonese, Paolo, Rasia, Sarah, Realmuto, Sabrina, Repice, Anna, Rigoni, Eleonora, Rilla, Maria Teresa, Rinaldi, Francesca, Romano, Calogero Marcello, Ronzoni, Marco, Rovaris, Marco, Ruscica, Francesca, Sabattini, Loredana, Salemi, Giuseppe, Saraceno, Lorenzo, Sartori, Alessia, Sartori, Arianna, Sbragia, Elvira, Scarano, Giuditta Ilaria, Scarano, Valentina, Schillaci, Valentina, Sessa, Maria, Sgarito, Caterina, Sibilia, Grazia, Siciliano, Gabriele, Signori, Alessio, Signoriello, Elisabetta, Sinisi, Leonardo, Sireci, Francesca, Sola, Patrizia, Solaro, Claudio, Sotgiu, Stefano, Sparaco, Maddalena, Stromillo, Maria Laura, Strumia, Silvia, Susani, Emanuela Laura, Tabiadon, Giulietta, Teatini, Francesco, Tomassini, Valentina, Tonietti, Simone, Torri, Clerici Valentina, Tortorella, Carla, Toscano, Simona, Totaro, Rocco, Trotta, Maria, Turano, Gabriella, Ulivelli, Monica, Valentino, Manzo, Vaula, Giovanna, Vecchio, Domizia, Vercellino, Marco, Verrengia, Elena Pinuccia, Vianello, Marika, Virgilio, Eleonora, Vitetta, Francesca, Vollaro, Stefano, Zaffaroni, Mauro, Zampolini, Mauro, Zarbo, Ignazio Roberto, and Zuliani, Luigi

Published
2022
Full Text
View/download PDF

9. Breakthrough SARS-CoV-2 infections after COVID-19 mRNA vaccination in MS patients on disease modifying therapies during the Delta and the Omicron waves in Italy

Author

Sormani, Maria Pia, primary, Schiavetti, Irene, additional, Inglese, Matilde, additional, Carmisciano, Luca, additional, Laroni, Alice, additional, Lapucci, Caterina, additional, Visconti, Valeria, additional, Serrati, Carlo, additional, Gandoglia, Ilaria, additional, Tassinari, Tiziana, additional, Perego, Germana, additional, Brichetto, Giampaolo, additional, Gazzola, Paola, additional, Mannironi, Antonio, additional, Stromillo, Maria Laura, additional, Cordioli, Cinzia, additional, Landi, Doriana, additional, Clerico, Marinella, additional, Signoriello, Elisabetta, additional, Cocco, Eleonora, additional, Frau, Jessica, additional, Ferrò, Maria Teresa, additional, Di Sapio, Alessia, additional, Pasquali, Livia, additional, Ulivelli, Monica, additional, Marinelli, Fabiana, additional, Pizzorno, Matteo, additional, Callari, Graziella, additional, Iodice, Rosa, additional, Liberatore, Giuseppe, additional, Caleri, Francesca, additional, Repice, Anna Maria, additional, Cordera, Susanna, additional, Battaglia, Mario Alberto, additional, Salvetti, Marco, additional, Franciotta, Diego, additional, Uccelli, Antonio, additional, Maglione, Alessandro, additional, Sapio, Alessia Di, additional, Signori, Alessio, additional, Iovino, Aniello, additional, Maria Repice, Anna, additional, Gabri Nicoletti, Carolina, additional, Mancinelli, Chiara Rosa, additional, Bezzini, Daiana, additional, Carmagnini, Daniele, additional, Brogi, Davide, additional, Nobile Orazio, Eduardo, additional, Nako, Enri, additional, Assandrir, Ester, additional, Baldi, Federica, additional, Ansaldi, Filippo, additional, Bovis, Francesca, additional, Siciliano, Gabriele, additional, Cola, Gaia, additional, Lus, Giacomo, additional, Icardi, Giancarlo, additional, Bellucci, Gianmarco, additional, Da Rin, Giorgio, additional, Alessandra Marfia, Girolama, additional, Vazzoler, Giulia, additional, Trivelli, Giuseppe, additional, Maietta, Ilaria, additional, Sticchi, Laura, additional, Lorefice, Lorena, additional, Ruggiero, Lucia, additional, Manzino, Marcello, additional, Monti Bragadin, Margherita, additional, Chiara Buscarinu, Maria, additional, Gagliardi, Maria, additional, Laura Stromillo, Maria, additional, Pia Sormani, Maria, additional, Rilla, Maria Teresa, additional, Alberto Battaglia, Mario, additional, Ponzano, Marta, additional, Fronza, Marzia, additional, Del Sette, Massimo, additional, Scialabba, Matteo, additional, Bedognetti, Michele, additional, De Rossi, Nicola, additional, De Stefano, Nicola, additional, Bigi, Rachele, additional, Dubbioso, Raffaele, additional, Reniè, Roberta, additional, Fabbri, Sabrina, additional, Rasia, Sarah, additional, Rolla, Simona, additional, Platzgummer, Stefan, additional, and Carlini, Valentina, additional

Published
2022
Full Text
View/download PDF

13. Ocrelizumab for the Treatment of Multiple Sclerosis: Safety, Efficacy, and Pharmacology

Author

Mancinelli,Chiara Rosa, De Rossi,Nicola, and Capra,Ruggero

Subjects
Therapeutics and Clinical Risk Management
Abstract

Chiara Rosa Mancinelli, Nicola De Rossi, Ruggero Capra Multiple Sclerosis Centre, Spedali Civili di Brescia, Brescia, ItalyCorrespondence: Chiara Rosa MancinelliMultiple Sclerosis Centre - Spedali Civili di Brescia, Via Ciotti, 154, Montichiari (BS), Brescia, 25018, ItalyTel +39 0309963474Fax +39 0309963475Email mancinellichiara86@gmail.comAbstract: The success of selective B-cells depleting therapies, as the anti-CD20 antibodies, in patients with multiple sclerosis (MS) has confirmed that B-cells are critical in the immune pathogenesis of the disease. Ocrelizumab, a humanized monoclonal antibody that selectively targets CD20+ B-cells, profoundly suppresses acute inflammatory disease activity, representing a highly effective therapy for relapsing-remitting multiple sclerosis (RRMS). It is also the first proven therapy able to slow disability progression in primary progressive multiple sclerosis (PPMS), particularly in patients with signs of acute radiological activity before being enrolled. Effectiveness has widely been demonstrated in randomized clinical trials (RCTs), and recently confirmed in open-label extension trials. Here, we review the role of B-cells in MS, the mechanism of action of ocrelizumab, its pharmacokinetics and pharmacodynamics, and the clinical data supporting its use, as well as safety data. We focus on issues related to the maintenance of immunocompetence, essential to ensure an immune response to either a primary infection or a vaccination. Lastly, we discuss about the possible role of ocrelizumab as an exit strategy from natalizumab-treated patients at risk of developing multifocal progressive leukoencephalopathy. In view of using ocrelizumab chronically, collecting long-term safety data and finding strategies to minimize adverse events will be extremely relevant.Keywords: ocrelizumab, anti-CD20 therapies, relapsing-remitting multiple sclerosis, primary progressive multiple sclerosis

Published
2021

14. Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies

Author

Sormani, Maria Pia, primary, Inglese, Matilde, additional, Schiavetti, Irene, additional, Carmisciano, Luca, additional, Laroni, Alice, additional, Lapucci, Caterina, additional, Da Rin, Giorgio, additional, Serrati, Carlo, additional, Gandoglia, Ilaria, additional, Tassinari, Tiziana, additional, Perego, Germana, additional, Brichetto, Giampaolo, additional, Gazzola, Paola, additional, Mannironi, Antonio, additional, Stromillo, Maria Laura, additional, Cordioli, Cinzia, additional, Landi, Doriana, additional, Clerico, Marinella, additional, Signoriello, Elisabetta, additional, Frau, Jessica, additional, Ferrò, Maria Teresa, additional, Di Sapio, Alessia, additional, Pasquali, Livia, additional, Ulivelli, Monica, additional, Marinelli, Fabiana, additional, Callari, Graziella, additional, Iodice, Rosa, additional, Liberatore, Giuseppe, additional, Caleri, Francesca, additional, Repice, Anna Maria, additional, Cordera, Susanna, additional, Battaglia, Mario Alberto, additional, Salvetti, Marco, additional, Franciotta, Diego, additional, Uccelli, Antonio, additional, Maglione, Alessandro, additional, Signori, Alessio, additional, Iovino, Aniello, additional, Nicoletti, Carolina Gabri, additional, Mancinelli, Chiara Rosa, additional, Bezzini, Daiana, additional, Carmagnini, Daniele, additional, Brogi, Davide, additional, Orazio, Eduardo Nobile, additional, Cocco, Eleonora, additional, Nako, Enri, additional, Assandri, Ester, additional, Baldi, Federica, additional, Ansaldi, Filippo, additional, Bovis, Francesca, additional, Siciliano, Gabriele, additional, Cola, Gaia, additional, Lus, Giacomo, additional, Icardi, Giancarlo, additional, bellucci, gianmarco, additional, Rin, Giorgio Da, additional, Marfia, Girolama Alessandra, additional, Vazzoler, Giulia, additional, Trivelli, Giuseppe, additional, Maietta, Ilaria, additional, Sticchi, Laura, additional, Lorefice, Lorena, additional, Ruggiero, Lucia, additional, Manzino, Marcello, additional, Bragadin, Margherita Monti, additional, Buscarinu, Maria Chiara, additional, Gagliardi, Maria, additional, Sormani, Maria Pia, additional, Rilla, Maria Teresa, additional, Ponzano, Marta, additional, Fronza, Marzia, additional, Sette, Massimo Del, additional, Scialabba, Matteo, additional, Bedognetti, Michele, additional, De Rossi, Nicola, additional, De Stefano, Nicola, additional, Bigi, Rachele, additional, Dubbioso, Raffaele, additional, Reniè, Roberta, additional, Fabbri, Sabrina, additional, Rasia, Sarah, additional, Rolla, Simona, additional, Platzgummer, Stefan, additional, and Carlini, Valentina, additional

Published
2021
Full Text
View/download PDF

15. SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort study

Author

Sormani, Maria Pia, primary, Schiavetti, Irene, additional, Landi, Doriana, additional, Carmisciano, Luca, additional, De Rossi, Nicola, additional, Cordioli, Cinzia, additional, Moiola, Lucia, additional, Radaelli, Marta, additional, Immovilli, Paolo, additional, Capobianco, Marco, additional, Brescia Morra, Vincenzo, additional, Trojano, Maria, additional, Tedeschi, Gioacchino, additional, Comi, Giancarlo, additional, Battaglia, Mario Alberto, additional, Patti, Francesco, additional, Fragoso, Yara Dadalti, additional, Sen, Sedat, additional, Siva, Aksel, additional, Furlan, Roberto, additional, Salvetti, Marco, additional, Abbadessa, Gianmarco, additional, Aguglia, Umberto, additional, Allegorico, Lia, additional, Allegri, Rossi Beatrice Maria, additional, Amato, Maria Pia, additional, Annovazzi, Pietro, additional, Antozzi, Carlo, additional, Appendino, Lucia, additional, Arena, Sebastiano, additional, Baione, Viola, additional, Balgera, Roberto, additional, Barcella, Valeria, additional, Baroncini, Damiano, additional, Barrilà, Caterina, additional, Battaglia, Mario A., additional, Bellacosa, Alessandra, additional, Bellucci, Gianmarco, additional, Bergamaschi, Roberto, additional, Bergamaschi, Valeria, additional, Bezzini, Daiana, additional, Biolzi, Beatrice, additional, Bisecco, Alvino, additional, Bonavita, Simona, additional, Borriello, Giovanna, additional, Bosa, Chiara, additional, Bosco, Antonio, additional, Bovis, Francesca, additional, Bozzali, Marco, additional, Brambilla, Laura, additional, Brescia, Morra Vincenzo, additional, Brichetto, Giampaolo, additional, Buccafusca, Maria, additional, Bucciantini, Elisabetta, additional, Bucello, Sebastiano, additional, Buscarinu, Maria Chiara, additional, Cabboi, Maria Paola, additional, Calabrese, Massimiliano, additional, Calabria, Francesca, additional, Caleri, Francesca, additional, Camilli, Federico, additional, Caniatti, Luisa Maria, additional, Cantello, Roberto, additional, Capra, Ruggero, additional, Capuano, Rocco, additional, Carta, Patrizia, additional, Cavalla, Paola, additional, Celani, Maria Grazia, additional, Cellerino, Maria, additional, Cerqua, Raffaella, additional, Chisari, Clara, additional, Clerici, Raffaella, additional, Clerico, Marinella, additional, Cocco, Eleonora, additional, Cola, Gaia, additional, Confalonieri, Paolo, additional, Conte, Antonella, additional, Conti, Marta Zaffira, additional, Cordano, Christian, additional, Cordera, Susanna, additional, Corea, Francesco, additional, Correale, Claudio, additional, Cottone, Salvatore, additional, Crescenzo, Francesco, additional, Curti, Erica, additional, d’Ambrosio, Alessandro, additional, D’Amico, Emanuele, additional, Danni, Maura Chiara, additional, d’Arma, Alessia, additional, Dattola, Vincenzo, additional, de Biase, Stefano, additional, De Luca, Giovanna, additional, De Mercanti, Stefania Federica, additional, De Mitri, Paolo, additional, De Stefano, Nicola, additional, Della Cava, Marco, additional, di Napoli, Mario, additional, Di Sapio, Alessia, additional, Docimo, Renato, additional, Dutto, Anna, additional, Evangelista, Luana, additional, Fanara, Salvatore, additional, Ferraro, Diana, additional, Ferrò, Maria Teresa, additional, Filippi, Massimo, additional, Fioretti, Cristina, additional, Fratta, Mario, additional, Frau, Jessica, additional, Fronza, Marzia, additional, Gajofatto, Alberto, additional, Gallo, Antonio, additional, Gallo, Paolo, additional, Gasperini, Claudio, additional, Ghazaryan, Anna, additional, Giometto, Bruno, additional, Gobbin, Francesca, additional, Govone, Flora, additional, Granella, Franco, additional, Grange, Erica, additional, Grasso, Maria Grazia, additional, Guareschi, Angelica, additional, Guaschino, Clara, additional, Guerrieri, Simone, additional, Guidetti, Donata, additional, Iaffaldano, Pietro, additional, Ianniello, Antonio, additional, Iasevoli, Luigi, additional, Imperiale, Daniele, additional, Infante, Maria Teresa, additional, Inglese, Matilde, additional, Iodice, Rosa, additional, Iovino, Aniello, additional, Konrad, Giovanna, additional, Lanzillo, Roberta, additional, Lapucci, Caterina, additional, Lavorgna, Luigi, additional, L’Episcopo Maria, Rita, additional, Leva, Serena, additional, Liberatore, Giuseppe, additional, Lo Re, Marianna, additional, Longoni, Marco, additional, Lopiano, Leonardo, additional, Lorefice, Lorena, additional, Lucchini, Matteo, additional, Lus, Giacomo, additional, Maimone, Davide, additional, Malentacchi, Maria, additional, Mallucci, Giulia, additional, Malucchi, Simona, additional, Mancinelli, Chiara Rosa, additional, Mancinelli, Luca, additional, Manganotti, Paolo, additional, Maniscalco, Teresa Giorgia, additional, Mantero, Vittorio, additional, Marangoni, Sabrina, additional, Marastoni, Damiano, additional, Marfia, Alessandra Girolama, additional, Marinelli, Fabiana, additional, Marti, Alessandro, additional, Martinelli Boneschi, Filippo, additional, Masserano Zoli, Federco, additional, Matta, Francesca, additional, Mendozzi, Laura, additional, Meucci, Giuseppe, additional, Miante, Silvia, additional, Miele, Giuseppina, additional, Milano, Eva, additional, Mirabella, Massimiliano, additional, Missione, Rosanna, additional, Moccia, Marcello, additional, Montepietra, Sara, additional, Monti Bragadin, Margherita, additional, Montini, Federico, additional, Motta, Roberta, additional, Nardone, Raffaele, additional, Nicoletti, Carolina Gabri, additional, Nobile-Orazio, Eduardo, additional, Nozzolillo, Agostino, additional, Onofrj, Marco, additional, Orlandi, Riccardo, additional, Palmieri, Anna, additional, Paolicelli, Damiano, additional, Pasquali, Livia, additional, Pastò, Luisa, additional, Pedrazzoli, Elisabetta, additional, Perini, Paola, additional, Pesci, Ilaria, additional, Petracca, Maria, additional, Petrone, Alfredo, additional, Piantadosi, Carlo, additional, Pietroboni, Anna M., additional, Pinardi, Federica, additional, Ponzano, Marta, additional, Portaccio, Emilio, additional, Pozzato, Mattia, additional, Pozzilli, Carlo, additional, Prosperini, Luca, additional, Protti, Alessandra, additional, Ragonese, Paolo, additional, Rasia, Sarah, additional, Realmuto, Sabrina, additional, Repice, Anna, additional, Rigoni, Eleonora, additional, Rilla, Maria Teresa, additional, Rinaldi, Francesca, additional, Romano, Calogero Marcello, additional, Ronzoni, Marco, additional, Rovaris, Marco, additional, Ruscica, Francesca, additional, Sabattini, Loredana, additional, Salemi, Giuseppe, additional, Saraceno, Lorenzo, additional, Sartori, Alessia, additional, Sartori, Arianna, additional, Sbragia, Elvira, additional, Scandellari, Cinzia, additional, Scarano Giuditta, Ilaria, additional, Scarano, Valentina, additional, Schillaci, Valentina, additional, Sessa, Maria, additional, Sgarito, Caterina, additional, Sibilia, Grazia, additional, Siciliano, Gabriele, additional, Signori, Alessio, additional, Signoriello, Elisabetta, additional, Sinisi, Leonardo, additional, Sireci, Francesca, additional, Sola, Patrizia, additional, Solaro, Claudio, additional, Sormani, Maria Pia, additional, Sotgiu, Stefano, additional, Sparaco, Maddalena, additional, Stromillo, Maria Laura, additional, Strumia, Silvia, additional, Susani, Laura Emanuela, additional, Tabiadon, Giulietta, additional, Teatini, Francesco, additional, Tomassini, Valentina, additional, Tonietti, Simone, additional, Torri, Clerici Valentina, additional, Tortorella, Carla, additional, Toscano, Simona, additional, Totaro, Rocco, additional, Trotta, Maria, additional, Turano, Gabriella, additional, Ulivelli, Monica, additional, Valentino, Manzo, additional, Vaula, Giovanna, additional, Vecchio, Domizia, additional, Vercellino, Marco, additional, Verrengia, Elena Pinuccia, additional, Vianello, Marika, additional, Virgilio, Eleonora, additional, Vitetta, Francesca, additional, Vollaro, Stefano, additional, Zaffaroni, Mauro, additional, Zampolini, Mauro, additional, Zarbo, Ignazio Roberto, additional, Zito, Antonio, additional, and Zuliani, Luigi, additional

Published
2021
Full Text
View/download PDF

17. Switching to ocrelizumab in RRMS patients at risk of PML previously treated with extended interval dosing of natalizumab.

Author

Mancinelli, Chiara Rosa, Scarpazza, Cristina, Cordioli, Cinzia, De Rossi, Nicola, Rasia, Sarah, Turrini, Maria Vittoria, and Capra, Ruggero

Subjects
*NATALIZUMAB, *MAGNETIC resonance imaging, *PROGRESSIVE multifocal leukoencephalopathy
Abstract

Discontinuation of natalizumab in patients with relapsing-remitting multiple sclerosis (RRMS) at risk of progressive multifocal leukoencephalopathy (PML) is associated with disease reactivation. Forty-two RRMS patients, who switched from an extended interval dose (EID) of natalizumab to ocrelizumab, underwent magnetic resonance imaging (MRI) and clinical monitoring during washout and after ocrelizumab starting. During the first 3 months, disease reactivation was observed in five (12%) patients; 6 months after ocrelizumab starting, no further relapses were recorded, and Expanded Disability Status Scale (EDSS) remained stable in 38 (90%) patients. In conclusion, ocrelizumab could be considered a choice to mitigate the risk of disease reactivation in patients previously treated with natalizumab-EID. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

18. Advances in the treatment of relapsing-remitting multiple sclerosis - critical appraisal of fingolimod

Author

Gasperini, Claudio, Ruggieri, Serena, Mancinelli, Chiara Rosa, and Pozzilli, Carlo

Subjects
Pharmacology, Chemical Health and Safety, patient satisfaction, Medicine (all), Toxicology and Pharmaceutics (all), Review, multiple sclerosis, Adherence, Fingolimod, Multiple sclerosis, Oral compounds, Patient satisfaction, Sphingosine-1-phosphate, Pharmacology (medical), Pharmacology, Toxicology and Pharmaceutics (all), Safety Research, sphingosine-1-phosphate, adherence, fingolimod, oral compounds
Abstract

Multiple sclerosis (MS) is a chronic inflammatory disorder of the central nervous system, traditionally considered to be an autoimmune, demyelinating disease. Based on this understanding, initial therapeutic strategies were directed at immune modulation and inflammation control. At present, there are five licensed first-line disease-modifying drugs for MS in Europe, and two second-line treatments. Currently available MS therapies have shown significant efficacy throughout many trials, but they produce different side effects. Despite disease-modifying drugs being well known and safe, they require regular and frequent parenteral administration and are associated with limited long-term treatment adherence. Therefore, the development of new therapeutic strategies is warranted. Several oral compounds are in late stages of development for treating MS. fingolimod is an oral sphingosine-1-phosphate receptor modulator that has demonstrated superior efficacy compared with placebo and interferon β-1a in phase III studies. It has already been approved in the treatment of MS. This review focuses on advances in current and novel oral treatment approaches in MS. We summarily review the oral compounds in this study, focusing on the recent development, approval, and the clinical experience with fingolimod.

Published
2013

19. Advances in the treatment of relapsing–remitting multiple sclerosis – critical appraisal of fingolimod

Author

Gasperini,Claudio, Ruggieri ,Serena, Mancinelli,Chiara Rosa, Pozzilli,Carlo, Gasperini,Claudio, Ruggieri ,Serena, Mancinelli,Chiara Rosa, and Pozzilli,Carlo

Abstract

Claudio Gasperini,1 Serena Ruggieri,2 Chiara Rosa Mancinelli,2 Carlo Pozzilli2 1Department of Neurosciences, S Camillo Forlanini Hospital, Rome, Italy; 2Department of Neurology and Psychiatry, Sapienza – University of Rome, Rome, Italy Abstract: Multiple sclerosis (MS) is a chronic inflammatory disorder of the central nervous system, traditionally considered to be an autoimmune, demyelinating disease. Based on this understanding, initial therapeutic strategies were directed at immune modulation and inflammation control. At present, there are five licensed first-line disease-modifying drugs for MS in Europe, and two second-line treatments. Currently available MS therapies have shown significant efficacy throughout many trials, but they produce different side effects. Despite disease-modifying drugs being well known and safe, they require regular and frequent parenteral administration and are associated with limited long-term treatment adherence. Therefore, the development of new therapeutic strategies is warranted. Several oral compounds are in late stages of development for treating MS. Fingolimod is an oral sphingosine-1-phosphate receptor modulator that has demonstrated superior efficacy compared with placebo and interferon β-1a in phase III studies. It has already been approved in the treatment of MS. This review focuses on advances in current and novel oral treatment approaches in MS. We summarily review the oral compounds in this study, focusing on the recent development, approval, and the clinical experience with fingolimod. Keywords: multiple sclerosis, oral compounds, fingolimod, sphingosine-1-phosphate, patient satisfaction, adherence

Published
2013

20. From High- to Low-Frequency Administered Interferon-Beta for Multiple Sclerosis: A Multicenter Study

Author

Prosperini, Luca, primary, Mancinelli, Chiara Rosa, additional, Pozzilli, Carlo, additional, Grasso, Maria Grazia, additional, Clemenzi, Alessandro, additional, Collorone, Sara, additional, Pontecorvo, Simona, additional, Francia, Ada, additional, Villani, Veronica, additional, Koudriavtseva, Tatiana, additional, Buttari, Fabio, additional, Centonze, Diego, additional, Di Battista, Giancarlo, additional, Frisullo, Giovanni, additional, Galgani, Simonetta, additional, and Gasperini, Claudio, additional

Published
2014
Full Text
View/download PDF

23. Interferon beta failure predicted by EMA criteria or isolated MRI activity in multiple sclerosis.

Author

Prosperini, Luca, Mancinelli, Chiara Rosa, De Giglio, Laura, De Angelis, Floriana, Barletta, Valeria, and Pozzilli, Carlo

Subjects
*TREATMENT effectiveness, *INTERFERON beta-1a, *MULTIPLE sclerosis, *MULTIPLE sclerosis treatment, *MAGNETIC resonance imaging, *PATIENTS
Abstract

The article presents a study on the four-year outcomes of interferon beta (IFNB)-treated patients with multiple sclerosis (MS). The study used clinical or magnetic resonance imaging (MRI) activity status of the patients during their first year of treatment. The result showed that no difference between the four-year outcomes of patients with isolated MRI activity from those fulfilling European Medicines Agency (EMA) criteria at first year of IFNB treatment.

Published
2014
Full Text
View/download PDF

24. Balance deficit with opened or closed eyes reveals involvement of different structures of the central nervous system in multiple sclerosis.

Author

Prosperini, Luca, Petsas, Nikolaos, Raz, Eytan, Sbardella, Emilia, Tona, Francesca, Mancinelli, Chiara Rosa, Pozzilli, Carlo, and Pantano, Patrizia

Subjects
MULTIPLE sclerosis, CENTRAL nervous system, VIRUS diseases, EFFERENT pathways, SPINAL cord
Abstract

The article discusses a study which was aimed to evaluate whether balance deficit in patients with multiple sclerosis (MS), as assessed with eyes opened (EO) and closed (EC), is associated with damage of different structures of the central nervous system (CNS). The study concluded that balance deficit in patients with MS was related to atrophy of both the cerebellum and spinal cord.

Published
2014
Full Text
View/download PDF

25. Risk of disease relapse following COVID-19 vaccination in patients with AQP4-IgG-positive NMOSD and MOGAD

Author

Dinoto, Alessandro, Sechi, Elia, Ferrari, Sergio, Gajofatto, Alberto, Orlandi, Riccardo, Solla, Paolo, Maccabeo, Alessandra, Maniscalco, Giorgia Teresa, Andreone, Vincenzo, Sartori, Arianna, Manganotti, Paolo, Rasia, Sarah, Capra, Ruggero, Mancinelli, Chiara Rosa, and Mariotto, Sara

Abstract

•We studied 56 patients with AQP4-IgG+NMOSD (n = 26) or MOGAD (n = 30) who received at least one dose of SARS-CoV-2 vaccination (mRNA-based).•Disease relapses within 1 month of vaccination occurred in only one patient with AQP4-IgG+NMOSD (4%).•The frequency of disease relapses was higher in patients who contracted SARS-CoV-2 infection before the vaccine (20%; 1/5).•In patients with AQP4-IgG+NMOSD or MOGAD the benefits of SARS-CoV-2 vaccination outweigh the risk of potential disease reactivation.

Published
2021
Full Text
View/download PDF

26. Balance deficit with opened or closed eyes reveals involvement of different structures of the central nervous system in multiple sclerosis.

Author

Prosperini L, Petsas N, Raz E, Sbardella E, Tona F, Mancinelli CR, Pozzilli C, and Pantano P

Subjects
Adult, Atrophy, Brain pathology, Female, Humans, Image Interpretation, Computer-Assisted, Magnetic Resonance Imaging, Male, Middle Aged, Multiple Sclerosis complications, Somatosensory Disorders etiology, Spinal Cord pathology, Multiple Sclerosis pathology, Neurologic Examination methods, Postural Balance physiology, Somatosensory Disorders pathology
Abstract

Objective: To evaluate whether balance deficit in patients with multiple sclerosis (MS), as assessed with eyes opened (EO) and closed (EC), is associated with damage of different structures of the central nervous system (CNS)., Methods: Fifty patients with MS and 20 healthy controls (HCs) underwent static posturography to calculate the body's center of pressure displacement (COP path) with EO and EC. They were scanned using a 3.0T magnet to obtain PD/T2 and 3D-T1-weighted images of the brain and spinal cord. We determined the mid-sagittal cerebellum area (MSCA) and upper cervical cord cross-sectional area (UCCA). We also measured the patients' lesion volumes (T2-LVs) on the whole brain and at different infratentorial levels., Results: MS patients had wider COP paths with both EO and EC (p < 0.001), and lower values in both MSCA (p = 0.01) and UCCA (p = 0.008) than HCs. The COP path with EO was associated with MSCA (Beta = -0.58; p = 0.004) and T2-LV on middle cerebellar peduncles (Beta = 0.59; p = 0.002). The COP path with EC was associated with UCCA (Beta= -22.74; p = 0.003) and brainstem T2-LV (Beta = 0.52; p = 0.01)., Conclusions: Balance deficit in MS was related to atrophy of both the cerebellum and spinal cord, but the extent of COP path under the two different conditions (EO or EC) implied different patterns of damage in the CNS.

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results